Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib Combinations in Relapsed/Refractory Follicular Lymphoma
NCT05867030Phase 1Withdrawn
- Sponsor
- Innovent Biologics
- Start
- Jul 2023
- Primary completion
- Aug 2029
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of parsaclisib in follicular lymphoma (FL) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Complete Response Rate at 6 months, Treatment-Emergent Adverse Events at 6 months and 1 more. Planned start Jul 2023; status: withdrawn.
02
Drugs
parsaclisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05867030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867030.